Business
Aeterna Zentaris Affirms Fundamental Strength of Business
Aeterna Zentaris Affirms Fundamental Strength of Business Aeterna Zentaris Affirms...
About this update from Cosciens Biopharma Inc.
[{"type":"text","content":"\n\n\n\nAeterna Zentaris Affirms Fundamental Strength of Business\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nAeterna Zentaris Affirms Fundamental Strength of Business\nCanada NewsWire\nQUEBEC CITY, Nov. 25, 2015\n\n\n\nQUEBEC CITY, Nov. 25, 2015 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the \"Company\"), affirms that its business and prospects remain fundamentally strong and highlights the following developments:\n\n\nZoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to continue the ZoptEC Phase 3 clinical program to completion following review of the final interim efficacy and safety data \nZoptrex™ met Phase 2 Primary Endpoint in men with heavily pretreated castration- and Taxane-resistant prostate cancer \nFirst patient enrolled in the confirmatory Phase 3 clinical trial of Macrilen™ \nPromotion of Saizen® and EstroGel® by the Company's sales force continues to show promise \nDilution from Series B Share Purchase Warrants has been substantially eliminated\nCommenting about the fundamentals of the Company's business, Chairman, President and Chief Executive Officer David A Dodd stated, \"Yesterday's announcement regarding corporate developments, which was required by IIROC on behalf of the Toronto Stock Exchange, caused some to question the fundamentals of our business. I want to reiterate that we believe the fundamentals remain strong. We have two products in Phase 3. One of the products, Zoptrex™, is in the late stage of Phase 3. We instituted a confirmatory Phase 3 clinical trial of Macrilen™ after a panel of US and EU endocrinology experts advised us to continue to seek approval for the compound because of their confidence in its efficacy and because there currently is no FDA-approved diagnostic test for adult growth hormone deficiency. That Phase 3 study recently enrolled its first patient, keeping us on track to conclude it by the end of 2016.\"\n\nMr. Dodd also commented on the Company's business development efforts, saying \"We continue...